Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-cnmwb Total loading time: 0 Render date: 2024-07-19T16:20:46.829Z Has data issue: false hasContentIssue false

8 - Therapeutic decision making in BMT/SCT for Hodgkin lymphoma

Published online by Cambridge University Press:  31 July 2009

Reinhold Munker ,
Hillard M. Lazarus  and
Kerry Atkinson
Reinhold Munker
Affiliation:
Louisiana State University
Hillard M. Lazarus
Affiliation:
University Hospitals Case Medical Center
Kerry Atkinson
Affiliation:
University of Queensland
Get access
Type
Chapter
Information
The BMT Data Book , pp. 127 - 138
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anderlini, P, Saliba, R, Acholonu, S, et al. 2005 Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marr Transpl 35: 943–51.CrossRefPubMed
Connors, JM 2005. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 23: 6400–08.CrossRefGoogle ScholarPubMed
Hasenclever, D, and Diehl, V. 1998. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339: 1506–14.CrossRefGoogle ScholarPubMed
Kuruvilla, J, Nagy, T, Pintilie, M, et al. 2006 Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106: 353–60.CrossRefPubMed
Lavoie, JC, Connors, JM, Phillips, GL, et al. 2005 High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473–78.CrossRefPubMed
Lazarus, HM, Loberiza, FR, Zhang, MJ, et al. 2001 Autotransplants for Hodgkin's disease in first relapse or second remission : a report from the autologous blood and marrow transplant registry (ABMTR)Bone Marr Transpl 27: 387–96.CrossRef
Lazarus, HM, Rowlings, PA, Zhang, MJ et al. 1999 Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 17: 534–45.CrossRefPubMed
Lieskovsky, YYE, Donaldson, SS, Torres, MA, et al. 2004 High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease : results and prognostic indices. J Clin Oncol 22: 4532–40.CrossRefPubMed
Milpied, N, Fielding, AK, Pearce, RM, et al. 1996 Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 14: 572–78.PubMed
Peggs, KS, Hunter, A, Chopra, R, et al. 2005 Clinical evidence of a graft versus lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365: 1934–41.CrossRefPubMed
Porter, DL, Stadtmauer, EA, and Lazarus, HM. 2003. ‘GVHD’: graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning. Bone Marr Transpl 31: 739–46.CrossRefPubMed
Sureda, A, Constans, M, Iriondo, A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16: 625–33.CrossRef
Tubiana, M, Henry-Amar, M, Cardé, P, et al. 1989. Toward comprehensive management tailored to prognostic factors of clinical stages I and II in Hodgkin's disease. The EORTC lymphoma group controlled clinical trials:1964–87. Blood 73: 47–56.

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×